- If The Data Statistics Company Needs To Receive The Information Of Human Genetic Resources, Does It Need To Do Information Back Up And Filing?
- How To Do Information Back Up And Filing When Overseas Publishing Or Participating In International Conferences Involving The Open Use Of Human Genetic Resources Information?
- If The Project Has Been Filed For International Cooperation, But It Needs To Be Changed To International Cooperative Scientific Research For Approval Due To Some Reason, How Should It Be Handled?
- When The System Displays The Filing Number Of International Cooperative Clinical Trial, Then The Clinical Trial Can Be Carried Out Without Waiting For Public Release?
- How To Apply For Projects Beyond The Implementation Period Of The Approval For International Cooperative Scientific Research, If They Have Not Been Completed?
- Is It Necessary To Apply For Approval Of International Cooperative Scientific Research If The Involving Parties Of Ongoing Clinical Trial Project Change To Foreign Entities?
- For The Approved International Cooperation Projects, During The Application For Change, Can The Clinical Trial Be Continued With Subject Screening And Recruitment?
- Is It Necessary To Apply For Changes In International Cooperative Scientific Research Activities That Do Not Involve Changes In The Types, Quantities And Uses Of Human Genetic Resources?
- How To Change The Leading Site?
- Does The Sponsor Of The Clinical Trial For The Purpose Of Regulatory Approval Need To Be Consistent With The Clinical Trial Approval, Notice Or Filing And Publication Materials?
- In The Clinical Trial, The Sponsor, Contract Research Organization And Other Cooperative Parties Are All Chinese Entities, And Only EDC Suppliers Are Foreign Entity. Is It Necessary To Apply For Approval Of International Cooperative Scientific Research?
- Which Units Belong To “other Units” For International Cooperative Scientific Research Project?
Strategy Consulting
- Market Entry Strategy
- Regulatory Strategy
- Clinical Strategy
- China Localization Strategy
- Hainan Urgent Use Pathway
- Innovation Pathway
- Fast Track Pathway
- Digital Health Consulting
Registration Affairs
- Pre-market Registration
- Modification Registration
- Renewal Registration
- Request for Classification
- Legal Agent Representation
- NMPA Expert Panel Meeting
- NMPA Supplemental Notice
Quality Assurance
- Postmarket Surveillance Compliance (IFU, Label, GSP)
- Adverse Event Reporting
- Recall Handling
- Periodic Risk Evaluation Report
- Annual QMS Self-Inspection Report
- NMPA Inspections & Mock-Audit
- QMS Establishment/Audit/Remediation
- QA Gap Analysis
- Factory Audit
- Unique Device Identifier
Device Testing
- China Local Type Testing
- Device Modification Compliance Testing
- Biocompatibility Testing
- EMC Testing
Clinical Research Organization (CRO)
- Clinical Trials/Research
- Real-World Study
- China CER & MDR CER
- Clinical Evaluation Feasibility Assessment
Customized Training
- China Regulatory Training
- China QMS Training
- China GCP Training
- China Localization Training
- Periodic Regulatory Updates Training
Other Services
- Translation
- Patent & Trademark
- Distributor Evaluation & Audit
- KOL Interview/Consultation
- Investment
- Global regulatory services
